Compare BridgeBio Pharma Inc (BBIO) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs General Dynamics Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while General Dynamics Corporation trades at $392 (market cap $107.13B). The key difference: General Dynamics Corporation is far larger — about 6.4× BridgeBio Pharma Inc's market cap, and General Dynamics Corporation pays a 1.61% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GD | |
|---|---|---|
Market Cap | $16.61B | $107.13B |
Sector | Health | Industrials |
52-Week High | $90.17 | $395.97 |
52-Week Low | $47.29 | $312.53 |
Enterprise Value | $18.16B | $112.28B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
General Dynamics (GD) trades at $392.05, up 1.33% today, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $4.24 versus $3.96 expected, with revenue growth across all segments. A $76.6 billion Navy contract awarded in July 2026 bolsters its backlog to $136.5 billion, providing visibility for future growth.
The stock offers upside to the $427.40 consensus price target, driven by defense spending tailwinds and operational execution. Risks include valuation at a 23.91 P/E and potential contract execution delays. Analyst sentiment is positive with 57% buy ratings, but overbought RSI levels near-term may limit gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
